Antivirals for COVID-19: A critical review.
Clin Epidemiol Glob Health
; 9: 90-98, 2021.
Article
in English
| MEDLINE | ID: covidwho-2259572
ABSTRACT
No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as the development of antivirals usually requires time. Therefore, assessment and use of currently available antiviral drugs is critical for a timely response to the current pandemic. Here, we have reviewed anti-SARS-CoV-2 potencies of available antiviral drug groups such as fusion inhibitors, protease inhibitors, neuraminidase inhibitors, and M2 ion-channel protein blockers. Although clinical trials to assess the efficacy of these antivirals are ongoing, this review highlights important information including docking and modeling analyses, in vitro studies, as well as results from clinical uses of these antivirals against COVID-19 pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Language:
English
Journal:
Clin Epidemiol Glob Health
Year:
2021
Document Type:
Article
Affiliation country:
J.cegh.2020.07.006
Similar
MEDLINE
...
LILACS
LIS